Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Int Immunopharmacol ; 24(2): 267-275, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25533502

ABSTRACT

Butein (3,4,2',4'-tetrahydroxychalcone), a flavonoid derivative, has been reported to show several biological actions, including anti-inflammatory and anti-cancer. However, the possible molecular mechanisms involved are poorly understood. Treatment of human umbilical vein endothelial cells (HUVECs) with butein significantly inhibited cell surface intercellular adhesion molecule-1 (ICAM-1) expression, ICAM-1 protein synthesis, and mRNA expression induced by tumor necrotic factor-α (TNF-α) and/or phorbol 12-myristate 13-acetate (PMA). Electrophoretic mobility shift assay revealed that butein blocked activation of transcription factors, nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), induced by TNF-α and PMA. Moreover, butein abolished TNF-α- and PMA-induced IκBα phosphorylation, which participates in NF-κB activation, and PMA-induced phosphorylation of c-Jun, a subunit composed of AP-1. In vitro, butein inhibited the phosphorylation of c-Jun, binding to GST beads, mediated by JNK isolated from PMA-treated cells. The inhibitory action of butein on the JNK-mediated in vitro c-Jun phosphorylation was abrogated in the presence of ATP. These results indicate that in HUVECs, butein suppresses the expression of ICAM-1 mRNA and protein through the inhibition of the activation of NF-κB and AP-1 induced by TNF-α and PMA, that the inhibitory action of butein on NF-κB activation results from the inhibition of IκBα phosphorylation by IκB kinase (IKK), and that the inactivation of PMA-activated AP-1 by butein is due to the blocking of JNK-mediated c-Jun phosphorylation through the inhibition of ATP binding.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Chalcones/pharmacology , Endothelial Cells/drug effects , Intercellular Adhesion Molecule-1/metabolism , Proto-Oncogene Proteins c-jun/metabolism , Cells, Cultured , Endothelial Cells/physiology , Gene Expression Regulation/drug effects , Humans , I-kappa B Proteins/metabolism , Immunosuppression Therapy , Intercellular Adhesion Molecule-1/genetics , Phosphorylation/drug effects , Proto-Oncogene Proteins c-jun/genetics , Tetradecanoylphorbol Acetate/analogs & derivatives , Tetradecanoylphorbol Acetate/immunology , Transcription Factor AP-1/metabolism , Tumor Necrosis Factor-alpha/immunology , Umbilical Cord/cytology
2.
Yakugaku Zasshi ; 133(7): 773-82, 2013.
Article in Japanese | MEDLINE | ID: mdl-23811765

ABSTRACT

The aim of our study was to produce a new diabetic model by a single i.p. injection of various doses of streptozotocin (STZ) to 8-week-old male Institute of Cancer Research (ICR) mice. When STZ was i.p. injected at doses rainging from 75 to 200 mg/kg, in the group injected 200 mg/kg STZ, the non-fasting serum glucose levels markedly rose from 1 week after STZ administration and the high glucose levels were maintained for 9 weeks. The serum glucose levels in the group administered 100 mg/kg STZ were within a normal range at 1 week after STZ administration, but thereafter continued to increase gradually till 9 weeks. In contrast with the serum glucose levels, a marked reduction in the percentage of the relative numbers of ß-cells in the islets of pancreas from 1 week in mice injected 200 mg/kg STZ was observed. On the other hand, in 100 mg/kg STZ mice, the number of ß-cells was almost normal percentage at 1 week and then continued to gradually decrease as the time went on throughout 24-week-observation. These results indicate that only the 100 mg/kg STZ injection produces slowly progressive diabetes mellitus in mice. Low molecular weight (LMW) chitosan (chitosan lactate, average of molecular weight: 20000) was administered as drinking water from prediabetic stage (from 2 weeks after 100 mg/kg STZ injection). The 0.2% or 0.8% LMW chitosan administration prevented the progression of 100 mg/kg STZ-induced slowly progressive diabetes mellitus. The mechanisms, which LMW chitosan is effective in this model may be discussed on ß-cells.


Subject(s)
Chitosan/therapeutic use , Diabetes Mellitus, Experimental/prevention & control , Disease Models, Animal , Animals , Disease Progression , Male , Mice , Molecular Weight , Streptozocin
3.
Biol Pharm Bull ; 33(6): 963-70, 2010.
Article in English | MEDLINE | ID: mdl-20522960

ABSTRACT

In an acute treatment experiment, metformin (150, 300 mg/kg, per os (p.o.)) markedly reduced the consumption of a high-fat diet (HFD) (45 kcal% fat-containing diet) for 2 h after the HFD was given to the fasted male C57BL/6J (B6) mice. In addition, metformin at a higher dose increased plasma active glucagon-like peptide-1 (GLP-1) levels at 1 h after the HFD was given. On the other hand, pioglitazone (12 mg/kg, p.o.) slightly increased the food intake but did not affect active GLP-1 levels when given at 6 and 12 mg/kg, p.o. In a long-team experiment for 9 weeks, metformin treatment (0.25, 0.5% in the HFD) resulted in reduction of body weight gain and HFD intake. When wet weights of various body fat pads of each mouse were measured at 9 weeks after treatment, metformin markedly decreased these weights. However, pioglitazone treatment (0.01, 0.02% in the HFD) did not have obvious effects on these parameters. Oral glucose tolerance test was carried out after 20-h fasting at 4 weeks post-treatment. Whereas metformin treatment (0.25, 0.5%) markedly improved glucose intolerance, pioglitazone treatment (0.02%) slightly improved this parameter. At 9 weeks, both metformin and pioglitazone markedly improved hyperglycemia and hyperinsulinemia. Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective. These results indicate that metformin reduces body weight gain and improves glucose intolerance in HFD-induced obese diabetic B6 mice.


Subject(s)
Energy Intake/drug effects , Glucose Intolerance/drug therapy , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Obesity/drug therapy , Thiazolidinediones/therapeutic use , Weight Gain/drug effects , Animals , Blood Glucose/metabolism , Body Weight/drug effects , Dietary Fats/administration & dosage , Glucagon-Like Peptide 1/blood , Glucose Intolerance/blood , Glucose Tolerance Test , Hyperglycemia/blood , Hyperglycemia/drug therapy , Hyperinsulinism/blood , Hyperinsulinism/drug therapy , Hypoglycemic Agents/pharmacology , Insulin/blood , Leptin/blood , Male , Metformin/pharmacology , Mice , Mice, Inbred C57BL , Obesity/blood , Obesity/physiopathology , Pioglitazone , Thiazolidinediones/pharmacology
4.
J Immunol ; 184(9): 5253-62, 2010 May 01.
Article in English | MEDLINE | ID: mdl-20368270

ABSTRACT

MCP1 is upregulated by various stimuli, including LPS, high glucose, and hyperosmolality. However, the molecular mechanisms of transcriptional regulation of the MCP1 gene under hyperosmolar conditions are poorly understood. Treatment of NRK52E cells with NaCl or mannitol resulted in significant elevation of MCP1 mRNA and protein in a time- and dose-dependent manner. Treatment with a p38MAPK inhibitor (SB203580), an ERK inhibitor (PD98059), or an MEK inhibitor (U0126), suppressed the increase in MCP1 expression caused by hypertonic NaCl, whereas a JNK inhibitor (SP600125) and an AP1 inhibitor (curcumin) failed to attenuate MCP1 mRNA expression by NaCl. In the 5'-flanking region of the MCP1 gene, there is a sequence motif similar to the consensus TonE/ORE as well as the consensus C/E binding protein (BP), NF-kappaB, and AP1/Sp1 sites. Luciferase activity in cells transfected with reporter constructs containing a putative TonE/ORE element (MCP1-TonE/ORE) enhanced reporter gene expression under hypertonic stress. Results of electrophoretic gel mobility shift assay showed a slow migration of the MCP1-TonE/ORE probe, representing the binding of TonEBP/OREBP/NFAT5 to this enhancer element. These results indicate that the 5'-flanking region of MCP1 contains a hypertonicity-sensitive cis-acting element, MCP1-TonE/ORE, as a novel element in the MCP1 gene. Furthermore, p38MAPK and MEK-ERK pathways appear to be, at least in part, involved in hypertonic stress-mediated regulation of MCP1 expression through the MCP1-TonE/ORE.


Subject(s)
Chemokine CCL2/genetics , Enhancer Elements, Genetic/immunology , MAP Kinase Signaling System/genetics , MAP Kinase Signaling System/immunology , Transcription Factors/physiology , 5' Untranslated Regions/immunology , Animals , Cell Line , Chemokine CCL2/biosynthesis , Consensus Sequence/immunology , Enhancer Elements, Genetic/genetics , Gene Expression Regulation, Enzymologic/immunology , Hypertonic Solutions/pharmacology , Male , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/physiology , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/physiology , NFATC Transcription Factors/metabolism , Osmolar Concentration , Rats , Rats, Sprague-Dawley , Transcription Factors/metabolism , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/physiology
5.
Phys Chem Chem Phys ; 12(13): 3156-63, 2010 Apr 07.
Article in English | MEDLINE | ID: mdl-20237704

ABSTRACT

Effects of metal substrate on the bonding nature of isocyanide group of two aryl isocyanides, 1,4-phenylene diisocyanide (PDI) and 4-methylphenyl isocyanide (MPI), and tilt angle of MPI were examined by measuring sum frequency generation (SFG) spectra of the self-assembled monolayers (SAMs) of these molecules on Au, Pt, Ag, and Pd surfaces. The SFG peaks due to "metal bonded" and "free"-NC groups were resolved by comparing the SFG spectra of PDI with IR spectra obtained by DFT calculations and previous results of vibrational spectroscopy. Based on the peak positions of the "metal bonded"-NC, it is clarified that while PDI and MPI were adsorbed at top sites on Au, Ag, and Pt surfaces, they adsorbed at bridge sites on the Pd surface. The tilt angles of MPI were determined from the intensity ratio between the SFG peaks of C-H symmetric and asymmetric stretching vibrational modes of the CH(3) group. The tilt angles of the MPI SAMs were in the order of Pt < Pd < Ag < Au, reflecting the bonding nature between the -NC group and the substrate atoms.

6.
Biol Pharm Bull ; 33(2): 223-9, 2010.
Article in English | MEDLINE | ID: mdl-20118544

ABSTRACT

The present study was designed to clarify the effects of an ethanol extract of artichoke leaf on acute gastric mucosal injury in rats. Oral administration of artichoke leaf extract dose-dependently prevented absolute ethanol-induced (125-500 mg/kg) or restraint plus water immersion stress-induced gastric mucosal injury (1000-2000 mg/kg). The artichoke leaf extract contains 1% cynaropicrin and 0.8% chlorogenic acid as main components and 70% dextrin as a vehicle. Cynaropicrin at doses of 1/100 of artichoke leaf extract [ethanol-induced mucosal injury: 5 mg/kg, per os (p.o.); stress-induced mucosal injury: 20 mg/kg, p.o.] also prevented gastric mucosal injury in both animal models. However, dextrin and chlorogenic acid at doses contained in the leaf extract were ineffective in both models. When artichoke leaf extract was given orally to normal rats, it (500-2000 mg/kg, p.o.) dose-dependently increased gastric mucus content. In addition, it (125-500 mg/kg, p.o.) dose-dependently prevented the decrease in gastric mucus content by absolute ethanol. When the effects of artichoke leaf extract on basal gastric acid secretion in rats were evaluated, it (500-2000 mg/kg, p.o.) dose-dependently increased the volume of gastric juice in normal rats. However, it was ineffective in decreasing basal gastric acid secretion in normal rats. These results indicate that artichoke leaf extract is effective against acute gastritis and its beneficial effect is due to that of cynaropicrin. The gastric mucus-increasing action of artichoke leaf extract may be, at least in part, related to the anti-gastritic action of the extract.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Cynara scolymus , Gastric Mucosa/drug effects , Phytotherapy/methods , Plant Extracts/therapeutic use , Acute Disease , Animals , Anti-Ulcer Agents/isolation & purification , Cynara scolymus/chemistry , Cynara scolymus/physiology , Gastric Juice/drug effects , Gastric Juice/metabolism , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastritis/drug therapy , Gastritis/pathology , Male , Plant Extracts/isolation & purification , Plant Leaves , Rats , Rats, Sprague-Dawley
7.
Biol Pharm Bull ; 32(2): 276-82, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19182389

ABSTRACT

Progesterone (P) is an important hormone for the establishment of pregnancy, and its administration is useful for luteal insufficiency. Considering the problems of commercially available oral and injection drugs, hospital-formulated vaginal suppositories are clinically used. However, since the half-life of P suppositories is short, it is difficult to maintain its constant blood concentration. To sustain drug efficacy and prevent side-effects, we are attempting to develop sustained-release suppositories by examining the degree of sustained-release of active ingredients. In this study, we examined the combinations of granulation methods and release systems for the preparation of sustained-release granules of P, and produced 13 types of sustained-release granules. We also examined the diameter, content, and dissolution of each type of granules, and confirmed that the sustained-release of all types of granules was satisfactory. Among the sustained-release granules, we selected granules with a content and a degree of sustained-release suitable for sustained-release suppositories.


Subject(s)
Progesterone/administration & dosage , Suppositories , Acrylic Resins , Chemistry, Pharmaceutical , Delayed-Action Preparations , Drug Compounding , Excipients , Particle Size , Powders , Sodium Dodecyl Sulfate , Solubility
8.
Eur J Pharmacol ; 601(1-3): 143-7, 2008 Dec 28.
Article in English | MEDLINE | ID: mdl-18955044

ABSTRACT

In the present study, we compared the effects of alpha-tocopherol and probucol, antioxidants, on the healing of acetic acid-induced gastric ulcers in 8-, 48- and 96-week-old rats. The repeated oral administration of alpha-tocopherol (16 mg/kg twice daily) and probucol (1000 mg/kg twice daily) for 14 consecutive days markedly accelerated the gastric ulcer healing in 48- and 96-week-old rats as well as 8-week-old ones. The ulcer healing effects of both drugs were not significantly different among the rats at three different ages. The superoxide dismutase (SOD) activity in the ulcerated region of 8-, 48- and 96-week-old rats was markedly lower than that in the unulcerated region. In contrast, the thiobarbituric acid (TBA)-reactive substance content, an index of lipid peroxidation, in the ulcerated region of rats at three different ages markedly increased, as compared to that in the unulcerated region. The SOD activity tended to decrease with aging, while the TBA-reactive substance content gradually increased. The repeated administration of alpha-tocopherol and probucol accelerated the ulcer healing and inhibited the increase in the TBA-reactive substance content in the ulcerated region. These results suggest that alpha-tocopherol and probucol promote the ulcer healing by their potent antioxidant activities in 48- and 96-week-old rats as well as 8-week-old rats.


Subject(s)
Antioxidants/pharmacology , Probucol/pharmacology , Stomach Ulcer/drug therapy , alpha-Tocopherol/pharmacology , Acetic Acid , Administration, Oral , Aging , Animals , Anti-Ulcer Agents/pharmacology , Disease Models, Animal , Lipid Peroxidation/drug effects , Male , Rats , Rats, Wistar , Stomach Ulcer/physiopathology , Superoxide Dismutase/drug effects , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism
10.
J Clin Immunol ; 27(4): 409-29, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17516154

ABSTRACT

We investigated participation of monocyte chemoattractant protein-1 (MCP-1) in tubulointerstitial fibrosis and correlation between MCP-1 and proteinuria in Wistar-Kyoto (WKY) rats with glomerulonephritis induced by anti-glomerular basement membrane (anti-GBM) antibody. WKY rats showed marked proteinuria and severe glomerular crescent formation at 7 days post antibody injection. At 28 days, tubulointerstitial fibrotic lesions were observed, followed by sustained heavy proteinuria and severe tubulointerstitial fibrosis at 56 days. Histological examination revealed that the overlapped immunoreactivities of MCP-1, rat albumin, and p65NF-kappaB were detected in the same tubular segments of nephritic kidney, and a significant positive correlation was observed between proteinuria and MCP-1 expression in the tubulointerstitial fibrosis. ED-1- and CD8-positive cells were also abundant, and there was a good correlation between monocyte/macrophage recruitment and MCP-1 expression in the tubulointerstitial area. These results suggest that MCP-1 participates in the progression of tubulointerstitial fibrosis, through massive albuminuria, which is accompanied by marked monocyte/macrophage recruitment.


Subject(s)
Anti-Glomerular Basement Membrane Disease/immunology , Chemokine CCL2/immunology , Kidney/immunology , Nephritis, Interstitial/immunology , Proteinuria/immunology , Animals , Anti-Glomerular Basement Membrane Disease/chemically induced , Chemokine CCL2/genetics , Chemokine CCL2/urine , Creatinine/blood , Creatinine/urine , Disease Models, Animal , Disease Progression , Fibrosis/chemically induced , Fibrosis/immunology , Fibrosis/pathology , Gene Expression Regulation , Kidney/chemistry , Kidney/pathology , Male , Nephritis, Interstitial/chemically induced , Proteinuria/chemically induced , Proteinuria/urine , Rats , Rats, Inbred Lew , Rats, Inbred WKY , Rats, Wistar , Species Specificity , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism
11.
Biol Pharm Bull ; 29(11): 2206-13, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17077516

ABSTRACT

Oral administration of tea catechin dose-dependently prevented absolute ethanol-induced (50, 100, 200 mg/kg) or restraint plus water immersion stress-induced acute gastric mucosal injury (300, 400 mg/kg) in rats. When the effect of test compound was evaluated on the 15th day after acetic acid injection to rats, repeated oral administration of tea catechin (25, 50, 100 mg/kg twice daily) dose-dependently accelerated the healing of acetic acid-induced chronic gastric ulcers. Tea catechin (10(-5)-10(-1) g/100 ml) concentration-dependently scavenged superoxide anions in vitro. Tea catechin (100, 200 mg/kg orally) markedly inhibited the increase in thiobarbituric acid-reactive substances in the injured mucosa of rats treated with 50% ethanol. Tea catechin (50, 100 mg/kg twice orally, daily) markedly inhibited the increase in content of thiobarbituric acid-reactive substances in the ulcerated region of acetic acid-induced gastric ulcers on the 7th and 15th days. In addition, at 50, 100 and 200 mg/kg orally, it dose-dependently prevented the decrease in gastric mucosal hexosamine content induced by absolute ethanol, although it failed to inhibit the basal gastric acid secretion. These results suggest that tea catechin may primarily protect gastric mucosa from acute gastric mucosal injury and promote the healing of chronic gastric ulcers by its antioxidant activity and gastric mucus-increasing actions.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Camellia sinensis/chemistry , Catechin/therapeutic use , Stomach Ulcer/prevention & control , Tea/chemistry , Acetic Acid/administration & dosage , Acetic Acid/toxicity , Administration, Oral , Animals , Anti-Ulcer Agents/administration & dosage , Anti-Ulcer Agents/chemistry , Catechin/administration & dosage , Catechin/chemistry , Dose-Response Relationship, Drug , Ethanol/administration & dosage , Ethanol/toxicity , Free Radical Scavengers/antagonists & inhibitors , Free Radical Scavengers/metabolism , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Hexosamines/metabolism , Immersion/adverse effects , Male , Molecular Structure , Omeprazole/administration & dosage , Omeprazole/therapeutic use , Phytotherapy/methods , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism , Restraint, Physical/adverse effects , Restraint, Physical/methods , Stomach Ulcer/chemically induced , Stomach Ulcer/metabolism , Sucralfate/administration & dosage , Sucralfate/therapeutic use , Thiobarbituric Acid Reactive Substances/metabolism
12.
Eur J Pharmacol ; 548(1-3): 174-80, 2006 Oct 24.
Article in English | MEDLINE | ID: mdl-16979162

ABSTRACT

We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on renal damage in streptozotocin-induced diabetic rats fed a high cholesterol diet. Increases in urinary albumin and lipid peroxide excretions were observed in these diabetic rats, when both urinary parameters were measured at 8 and 15 weeks after streptozotocin administration. Daily treatment with probucol, insulin, or their combination markedly suppressed the increase in the 24 h urinary albumin and lipid peroxide excretions. Furthermore, glycogen degeneration of distal tubules, fatty degeneration of glomerular endothelium, and hypertrophy of glomeruli and mesangium were observed in the kidneys of the diabetic animals, when histopathological evaluation was performed at 4, 8 and 15 weeks (glomerular and mesangial hypertrophy was observed only at 15 weeks). Combined probucol and insulin treatment was the most effective in suppressing these renal histopathological changes. These results indicate that combined treatment with probucol and insulin is useful in preventing the progression of renal damage in diabetic rats. The possible mechanisms for the preventive effect of this combined treatment will be discussed.


Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Insulin/pharmacology , Kidney Diseases/drug therapy , Probucol/pharmacology , Albuminuria , Animals , Anticholesteremic Agents/pharmacology , Blood Glucose , Cholesterol/blood , Cholesterol, Dietary , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Drug Synergism , Drug Therapy, Combination , Hypoglycemic Agents/pharmacology , Kidney Diseases/etiology , Kidney Diseases/metabolism , Kidney Diseases/pathology , Lipid Peroxides/urine , Male , Rats , Rats, Sprague-Dawley , Triglycerides/blood
13.
Biol Pharm Bull ; 29(6): 1110-9, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16755002

ABSTRACT

We have already reported that slowly progressive non-insulin-dependent diabetes mellitus (NIDDM) is produced by a single i.p. injection of a subdiabetogenic dose (100 mg/kg) of streptozotocin (STZ) to 8-week-old male ICR mice. The aim of the present study was to clarify whether or not the progressive NIDDM is induced in ddY, BALB/c, C57BL/6 and ICR mice by the administration of STZ. Eight-week-old male mice of the 4 different strains were administered a single i.p. injection of STZ at various doses (ICR, ddY and BALB/c: 100-200 mg/kg; C57BL/6: 75-150 mg/kg). Among the ddY, BALB/c and C57BL/6 mice, a time course-related rise in non-fasting serum glucose levels throughout the observation period of 1-12 weeks after STZ administration was only induced in the 125 mg/kg STZ ddY and 100 mg/kg STZ ICR mice. In contrast with serum glucose levels, the area of islets and the percentage of the relative number of insulin-immunoreactive cells (beta-cells) to glucagon-immunoreactive cells (alpha-cells) in the 100 mg/kg STZ ICR and 125 mg/kg STZ ddY mice continued to decrease gradually over time. In addition, in low dose STZ mice of both strains, the insulin response to glucose stimulation was extremely impaired over time, although non-fasting serum insulin levels were maintained near normal levels. The rate of the progression of diabetes was faster in the 125 mg STZ ddY mice than in the 100 mg/kg STZ ICR mice.


Subject(s)
Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Type 2/chemically induced , Mice , Streptozocin/toxicity , Animals , Blood Glucose/analysis , Cholesterol/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/urine , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/urine , Drinking , Eating , Glucose Tolerance Test , Immunohistochemistry , Injections, Intraperitoneal , Insulin/blood , Male , Mice, Inbred Strains , Species Specificity , Urine
14.
Hinyokika Kiyo ; 52(4): 265-70, 2006 Apr.
Article in Japanese | MEDLINE | ID: mdl-16686353

ABSTRACT

The data of sexually transmitted urethritis in males have been collected at 24 institutes in Kyoto Prefecture since October, 2002. The data collected from January to December in 2004 are summarized herein. A total of 1,275 patients were diagnosed with urethritis during this period. Microbiological examinations isolated Neisseria gonorrhoeae alone in 368 (29%), Chlamydia tracomatis alone in 336 (26%), both in 85 (7%), and others in 453 (36%). Male patients under 20 years old tended to have Chlamydial urethritis, alone or combined with gonococcal infection, and had a predominant infectious source, a non-commercial-sexual-worker female partner, suggesting a profound problem in sexual life of adolescents. The urologist preferred to use quinolones as the first therapeutic modality against male urethritis. However, drug resistance of N. gonorrhoeae, especially against quinolones, has rapidly progressed, which was also observed by a sensitivity examination test. Antibiotics should be used adequately against male urethrits according to the recent guidelines.


Subject(s)
Sexual Partners , Sexually Transmitted Diseases, Bacterial/epidemiology , Urethritis/epidemiology , Adolescent , Adult , Chlamydia Infections/drug therapy , Chlamydia Infections/epidemiology , Chlamydia trachomatis/isolation & purification , Gonorrhea/drug therapy , Gonorrhea/epidemiology , Humans , Japan/epidemiology , Male , Middle Aged , Neisseria gonorrhoeae/isolation & purification , Sexually Transmitted Diseases, Bacterial/drug therapy , Urethritis/drug therapy
15.
Biol Pharm Bull ; 28(11): 2080-6, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16272693

ABSTRACT

In the present study, we investigated the effects of a long-term treatment with vitamin E, an antioxidant vitamin, insulin, or their combination on renal damage in streptozotocin (STZ)-induced diabetic rats fed a high cholesterol diet. Increases in urinary albumin and lipid peroxide (LPO) excretions were observed in these diabetic rats, when both urinary parameters were measured at 8 and 15 weeks after STZ administration. Daily treatment with vitamin E, insulin, or their combination markedly suppressed the increase in the 24 h urinary albumin and lipid peroxide excretions. Furthermore, glycogen degeneration of distal tubules, fatty degeneration of glomerular endothelium and hypertrophy of glomeruli and mesangium were observed in the kidneys of the diabetic animals when histopathological evaluation was performed at 4, 8, and 15 weeks (glomerular and mesangial hypertrophy were observed only at 15 weeks). Combined vitamin E and insulin treatment was the most effective at suppressing these renal histopathological changes. These results indicate that combined vitamin E and insulin treatment additively prevents the development and progression of renal damage in diabetic rats. Possible mechanisms for the preventive effect of this combined treatment are discussed.


Subject(s)
Antioxidants/pharmacology , Cholesterol, Dietary/toxicity , Diabetic Nephropathies/pathology , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Kidney/pathology , Vitamin E/pharmacology , Vitamins/pharmacology , Albuminuria/metabolism , Animals , Blood Glucose/metabolism , Cholesterol/blood , Diabetes Mellitus, Experimental/pathology , Drug Synergism , Free Radical Scavengers/metabolism , Male , Rats , Rats, Sprague-Dawley , Triglycerides/blood
16.
Eur J Pharmacol ; 513(1-2): 159-68, 2005 Apr 18.
Article in English | MEDLINE | ID: mdl-15869753

ABSTRACT

We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet. Each rat was checked for cataracts at 0, 1, 2, 4, 8, 12 and 15 weeks after streptozotocin injection. Cataracts were observed from 8 weeks in untreated hypercholesterolemic and diabetic rats and the incidence of catarats increased to 100% by 15 weeks. The incidence of cataracts in rats treated with probucol, insulin and their combination was first seen at 12, 12 and 15 weeks, respectively, and was 86%, 63% and 33%, respectively, at 15 weeks. The preventive effects of both agents alone and their combination on the cataracts were confirmed by histopathological evaluation of eyeballs. The combined treatment with both agents markedly improved hyperglycemia, hyperlipidemia and increased serum lipid peroxide levels. These results indicate that the combined treatment with probucol and insulin is useful in preventing the development and progression of diabetic cataracts.


Subject(s)
Cataract/prevention & control , Cholesterol, Dietary/administration & dosage , Diabetes Mellitus, Experimental/complications , Insulin/pharmacology , Probucol/pharmacology , Animals , Blood Glucose/metabolism , Body Weight/drug effects , Cataract/etiology , Cataract/mortality , Cholesterol/blood , Diabetes Mellitus, Experimental/blood , Drug Therapy, Combination , Eating/drug effects , Eye/drug effects , Eye/pathology , Insulin/therapeutic use , Lipid Peroxides/blood , Male , Probucol/therapeutic use , Rats , Rats, Sprague-Dawley , Survival Rate , Time Factors , Triglycerides/blood
17.
Biol Pharm Bull ; 27(3): 338-44, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14993799

ABSTRACT

In the present study we investigated the effects of a long-term treatment with vitamin E, an antioxidant vitamin, insulin or their combination on cataracts of streptozotocin (STZ)-induced diabetic rats fed a high cholesterol diet. Each rat was checked for cataracts at 0, 1, 2, 4, 8, 12 and 15 weeks after STZ injection. Cataracts were observed from 8 weeks in the control diabetic rats and their incidence of catarats increased to 100% by 12 weeks. The incidence of cataracts in rats treated with vitamin E, insulin and their combination was first seen at 12 weeks and 56%, 20% and 10%, respectively, at 12 weeks and 78%, 50% and 20%, respectively, at 15 weeks. The preventive effects of either agent alone and their combination on the cataracts were in agreement with those obtained by histopathological evaluation of eyeballs. The combined treatment with both agents markedly improved hyperglycemia, hyperlipidemia and increased serum lipid peroxide levels. These results indicate that the combined treatment with vitamin E and insulin is useful in preventing the development and progression of diabetic cataracts.


Subject(s)
Antioxidants/therapeutic use , Cataract/prevention & control , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Vitamin E/therapeutic use , Animals , Antioxidants/administration & dosage , Blood Glucose/drug effects , Body Weight , Cataract/etiology , Cataract/pathology , Cholesterol/blood , Cholesterol, Dietary/administration & dosage , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Drug Therapy, Combination , Eating , Eye/pathology , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Lipid Peroxides/blood , Male , Rats , Rats, Sprague-Dawley , Triglycerides/blood , Vitamin E/administration & dosage
18.
Biol Pharm Bull ; 25(8): 1063-71, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12186411

ABSTRACT

The effects of SK-896, a new human motilin analogue ([Leu13]motilin-Hse), on digestive tract motility in postoperative ileus were evaluated in a dog model of ileus after laparotomy. SK-896 was intravenously administered at 0.17, 0.33 and 0.67 microg/kg starting soon after operation and then at 6-h intervals, for a total of 9 times. SK-896 progressively, dose-dependently and significantly increased the duodenal motility from 1 h after operation. The recovery time of the gastrointestinal-interdigestive migrating complex (GI-IMC) activity, which is an indicator of normal gastrointestinal tract activity after laparotomy, was 56.5 +/- 5.0 h in the control group. SK-896 significantly shortened this recovery time. On the other hand, the plasma SK-896 concentrations declined diexponentially after administration, and can be described by a linear pharmacokinetic model within the dose range used. In addition, the pharmacokinetics of SK-896 did not change significantly at any postoperative time. There was no correlation between the plasma SK-896 concentrations and the intensity of duodenal motility, because the activity in the duodenum decreased transiently 13 h after laparotomy and increased with time thereafter. The changes in the activity are considered to reflect the progressive changes in the state of ileus. In conclusion, SK-896 increased the duodenal motility significantly, shortening the recovery time of GI-IMC-like activity in dogs with post-laparotomy ileus. Therefore, it is expected from these results that SK-896 would be useful and effective for the treatment of gastroparalysis after abdominal surgery.


Subject(s)
Disease Models, Animal , Intestinal Obstruction/drug therapy , Motilin/analogs & derivatives , Motilin/therapeutic use , Postoperative Complications/drug therapy , Animals , Dogs , Gastrointestinal Motility/drug effects , Gastrointestinal Motility/physiology , Humans , Injections, Intravenous , Intestinal Obstruction/physiopathology , Laparotomy/adverse effects , Male , Motilin/blood , Motilin/pharmacology , Postoperative Complications/physiopathology
19.
Eur J Pharmacol ; 444(3): 209-15, 2002 May 31.
Article in English | MEDLINE | ID: mdl-12063082

ABSTRACT

In this study, we compared the effects of cimetidine and omeprazole on the healing of acetic acid-induced gastric ulcers in 8-, 48-, and 96-week-old rats. The repeated oral administration of cimetidine or omeprazole for 14 consecutive days markedly accelerated the ulcer healing in 8- and 48-week-old rats. However, both drugs were ineffective in 96-week-old rats. The basal gastric acid secretion of 8-, 48-, and 96-week-old rats decreased with aging. A single oral administration of cimetidine or omeprazole strongly decreased basal gastric acid secretion in the three different ages of rats. Cimetidine and omeprazole produced a potent and sustained serum gastrin-elevating action in 8- and 48-week-old rats. However, the gastrin-elevating actions of both drugs in 96-week-old rats were much weaker than in the 8- and 48-week-old rats. These results indicate that cimetidine and omeprazole have potent gastric ulcer healing actions in 8- and 48-week-old rats, as well as potent serum gastrin-elevating actions, but both drugs are ineffective in 96-week-old rats, which have lost their gastrin-elevating actions.


Subject(s)
Aging/physiology , Cimetidine/therapeutic use , Omeprazole/therapeutic use , Stomach Ulcer/drug therapy , Animals , Gastrins/blood , Male , Rats , Rats, Wistar , Stomach Ulcer/blood , Stomach Ulcer/chemically induced , Stomach Ulcer/physiopathology
20.
Biol Pharm Bull ; 25(2): 188-92, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11853163

ABSTRACT

Recently, we reported that low molecular weight (LMW) chitosan (chitosan lactate, average MW: 20,000) prevents the progression of low dose (100 mg/kg, i.p.) streptozotocin-induced slowly progressive diabetes mellitus in male ICR mice. The present study was designed to clarify the effects of LMW chitosan on hyperglycemia, hyperinsulinemia and hypertriglyceridemia in genetically obese diabetic male KK-Ay mice. LMW chitosan (0.05%, 0.2% or 0.8% water solution) was given daily as drinking water to male KK-Ay mice for 11 weeks, from 5 weeks of age. The non-fasting serum glucose levels of control mice continued to increase slowly throughout the experimental period. LMW chitosan lowered the serum glucose levels in a dose-dependent manner. In these diabetic mice, hyperinsulinemia and hypertriglyceridemia were observed, and LMW chitosan was dose-dependently effective in improving both serum biochemical parameters. LMW chitosan at three doses improved overdrinking and polyuria observed in these diabetic mice. It is concluded from these results that LMW chitosan may be useful for the treatment of obesity-related type 2 diabetes mellitus.


Subject(s)
Chitin/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Obesity/drug therapy , Animals , Blood Glucose/analysis , Body Weight/drug effects , Chitin/analogs & derivatives , Chitosan , Cholesterol/blood , Diabetes Mellitus, Type 2/metabolism , Disease Models, Animal , Drinking/drug effects , Eating/drug effects , Insulin/blood , Male , Mice , Mice, Inbred ICR , Molecular Weight , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...